RAPT Therapeutics, Inc. Schedule 13G/A (Amendment No. 2) was filed by RTW Investments, LP and Roderick Wong, M.D., reporting ownership information for the company's Common Stock, CUSIP 75382E208. The filing states the Reporting Persons each hold 0.0% of the class as of 03/31/2026 and list no voting or dispositive power.
The statement is a joint filing by RTW Investments (a Delaware limited partnership) and Dr. Wong as Managing Partner; signatures are dated 05/15/2026. The filing incorporates a Joint Filing Agreement by reference.
Positive
None.
Negative
None.
Insights
Amendment reports de minimis holdings and joint reporting.
The filing lists RTW Investments, LP and Roderick Wong, M.D. as joint reporting persons for RAPT Common Stock with 0.0% ownership as of 03/31/2026. It specifies zero sole or shared voting and dispositive power.
Because the statement documents ownership disclosure rather than an acquisition or disposition, its immediate investor impact is limited; subsequent filings would show any material change.
Filing follows Schedule 13G/A mechanics and cross‑references a Joint Filing Agreement.
The cover references CUSIP 75382E208 and incorporates Exhibit 99.1 (Joint Filing Agreement). The filing includes the business address for the Reporting Persons and the standard Itemized disclosures required under the Exchange Act.
Documented qualifiers and joint filing language are present; no proceeds or transactions are reported in this excerpt.
Key Figures
CUSIP:75382E208Ownership reported:0.0%Securities class:Common Stock, $0.0001 par value+3 more
6 metrics
CUSIP75382E208RAPT Common Stock
Ownership reported<percent>0.0%</percent>Amount beneficially owned as stated in Item 4(a)
Securities classCommon Stock, $0.0001 par valueTitle of class disclosed in Item 2(d)
Cover date03/31/2026Cover page header date
Signature date05/15/2026Signed by Roderick Wong, M.D.
Reporting persons' address40 10th Avenue, Floor 7, New York, NY 10014Business office listed in Item 2(b)
"This statement is filed by: RTW Investments, LP and Roderick Wong"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially ownedregulatory
"Amount beneficially owned: The information required by Item 4(a)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Joint Filing Agreementregulatory
"Exhibit 99.1 Joint Filing Agreement (incorporated by reference)"
What does the Schedule 13G/A amendment say about RAPT (RAPT) ownership?
It states RTW Investments and Roderick Wong each report 0.0% ownership of RAPT Common Stock. The filing shows zero sole or shared voting and dispositive power as of 03/31/2026.
Who filed the Amendment No. 2 Schedule 13G/A for RAPT?
The filing was made jointly by RTW Investments, LP and Roderick Wong, M.D. The business address is 40 10th Avenue, Floor 7, New York, NY 10014 and signatures are dated 05/15/2026.
Does the amendment report any voting or dispositive power for the filers?
No. The amendment explicitly reports 0 shares for sole or shared voting power and 0 shares for sole or shared dispositive power for each Reporting Person in the excerpt.
What security and CUSIP are referenced in the filing?
The filing concerns RAPT Therapeutics Common Stock, par value $0.0001, with CUSIP 75382E208. The cover page lists the date 03/31/2026 associated with the filing header.
Is there an agreement referenced with this Schedule 13G/A amendment?
Yes. The filing incorporates a Joint Filing Agreement as Exhibit 99.1 by reference to the Reporting Persons' prior submission filed on 05/15/2025.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
RAPT THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
75382E208
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
75382E208
1
Names of Reporting Persons
RTW Investments, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
75382E208
1
Names of Reporting Persons
Roderick Wong
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
RAPT THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of RAPT Therapeutics, Inc. (the "Company") directly held by the RTW Funds; and
(ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.
(c)
Citizenship:
RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
75382E208
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(b)
Percent of class:
RTW Investments: 0.0%
Dr. Wong: 0.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
RTW Investments: 0
Dr. Wong: 0
(ii) Shared power to vote or to direct the vote:
RTW Investments: 0 Shares
Dr. Wong: 0 Shares
(iii) Sole power to dispose or to direct the disposition of:
RTW Investments: 0
Dr. Wong: 0
(iv) Shared power to dispose or to direct the disposition of:
RTW Investments: 0 Shares
Dr. Wong: 0 Shares
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RTW Investments, LP
Signature:
/s/ Roderick Wong, M.D.
Name/Title:
Roderick Wong, M.D., Managing Partner
Date:
05/15/2026
Roderick Wong
Signature:
s/ Roderick Wong, M.D.
Name/Title:
Roderick Wong, M.D.
Date:
05/15/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on May 15, 2025).
